相关实验视频

Updated: Jan 8, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

高剂量RE辐射用于THOrax (RETHO) 中的现场复发性肺癌:第二阶段前性临床试验的结果

E Cammareri¹, M Duijm², P V Granton²

¹Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

International journal of radiation oncology, biology, physics

|December 22, 2025

概括

高剂量胸部再辐射有效治疗复发性肺癌,显著改善整体存活率和局部控制,可控毒性. 这种方法为在初始治疗后复发具有挑战性的患者提供了一个有前途的选择.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
临床试验临床试验

背景情况:

地方区域性失效发生在30%的初级肺癌病例中,这些病例发生在化疗后的放射治疗后.
对肺癌复发的再辐射具有重大临床挑战.
一项前性第二阶段试验评估了对边缘性或现场肺癌复发的胸部再辐射.

研究的目的:

评估高剂量胸部再辐射治疗复发性肺癌的疗效和安全性.
在患有复发性肺癌的患者中,实现12个月的平均整体存活期 (OS).
评估二级终点,包括局部控制 (LC),无病生存率 (DFS) 和毒性.

主要方法:

前性第二阶段试验,涉及患有复发性肺癌的患者,距离之前的50Gy10 EQD2同位素剂量线5厘米之内.
使用图像导向强度调制辐射疗法 (IMRT) 或体积调制弧线疗法 (VMAT) 进行的再辐射,剂量≥45Gy10 EQD2.
患者接受了常规分成型放射治疗或立体性身体辐射治疗 (SBRT).

主要成果:

平均生存期为30.1个月,明显超过了12个月的目标.
中位数局部控制 (LC) 为28.2个月,中位数无病生存 (DFS) 为13.6个月.
3级毒性发生在20%的患者中,主要是肺炎;没有观察到4-5级毒性.

结论:

高剂量的胸部再辐射是复发性肺癌的有效治疗方法.
该研究取得了有利的整体存活率,局部控制和无病存活率.
再辐射显示出有利的毒性概况,使其成为选定的患者的可行选择.

关键词:

高剂量再辐射高剂量再辐射肺癌是一种肺癌.幸存的生存方式

更多相关视频

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

相关概念视频

Pneumothorax-II

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...